Since IL-1 blockers were unavailable in Russia at the time of this study and tocilizumab (TCZ) was registered and approved for adults with rheumatoid arthritis (RA), we have been able to use TCZ off label for treatment of SoJIA, as the only option for management of SoJIA in patients unresponsive to other medications. Here, IL1B is linked to rheumatoid arthritis.